sellWeak cluster of 410b5-1 plan
Darlene Noci sold $2.5M of NUVL
Chief Development Officer at Nuvalent, Inc.. 20,000 shares at an average of $122.81, traded Jun 9, 2026, filed Jun 11, 2026.
Warning score
30Value
$2.5M
20,000 shares
Holdings after
58,117
-26% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$2.5M at market
- +10Share of holdings soldSold 26% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001862148-26-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | MOption exercise Class A Common Stock10b5-1 | +10,000 | $1.08 | $11k | 68,117 | Jun 11, 2026 |
| Jun 9, 2026 | MOption exercise Class A Common Stock10b5-1 | +685 | $6.89 | $4,720 | 68,802 | Jun 11, 2026 |
| Jun 9, 2026 | MOption exercise Class A Common Stock10b5-1 | +9,315 | $18.93 | $176k | 78,117 | Jun 11, 2026 |
| Jun 9, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $122.81 | $2.5M | 58,117 | Jun 11, 2026 |
| Jun 9, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 216 | Jun 11, 2026 |
| Jun 9, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -685 | $0.00 | $0 | 6,091 | Jun 11, 2026 |
| Jun 9, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,315 | $0.00 | $0 | 24,258 | Jun 11, 2026 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $261k 2,111 shares | -3% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.4M 11,430 shares | -12% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.8M 23,000 shares | -28% | |
| 16Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $679k 5,500 shares | -9% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $2.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $593k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $593k 5,500 shares | -9% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.1M 30,000 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.